Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harrow, Inc. - Common Stock
(NQ:
HROW
)
26.93
+0.04 (+0.13%)
Delayed Quote
Updated: 2:42 PM EST, Nov 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harrow, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio
November 02, 2026
From
PHIL Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
August 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
August 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
August 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
August 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
July 17, 2025
From
Harrow, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
July 06, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
July 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
June 18, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
June 09, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow to Present at Two Investor Conferences in May
May 14, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Announces First-Quarter 2025 Financial Results
May 08, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
May 05, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
April 10, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
March 27, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
March 27, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
March 24, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
March 17, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Launches VEVYE® Access for All
March 17, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
March 11, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
March 03, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
January 27, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
January 07, 2025
From
Harrow, Inc.
Via
Business Wire
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
November 21, 2024
From
Harrow, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
